MSD Global Health Innovation Fund | Activity | F4
MSD Global Health Innovation Fund Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
Press
Bill Taranto discussed GHI Fund's disciplined, patient-focused investing approach with Global Corporate Venturing. The secret of success for MSD's investment arm
3 investments · FEB 2026 – SEP 2026 Show all
Investment
Continued participation in N-Power Medicine's $32M Series B, alongside new strategic investor Labcorp Venture Fund. N-Power Medicine
Investment
Co-led Faro's $37.3M Series B for its agentic AI clinical development platform, alongside S32. Faro
Investment
Participated in Turbine's $25M Series B, led by Interactive Venture Partners, expanding Turbine's virtual cell platform into immunology. Turbine
Podcast
President Bill Taranto discussed why GHI Fund focuses on pharma services across drug development, supply chain, patient access, and real-world evidence. Bill Taranto on "Merck's GHI Fund and the Push to Rewire Pharma's Future"
Team Change
Alba Zurriaga Carda joined MSD Global Health Innovation Fund as an investment director after leaving Sanofi Ventures. Alba Zurriaga Carda joined as Investment Director
News
Investment Director Hanqing Li named a top-50 Rising Star in corporate venturing for 2025 by Global Corporate Venturing. Global Corporate Venturing Rising Stars 2025
New Fund
Launched MSD IDEA Studios accelerators in Singapore and Berlin, planning to invest $38M across both regions over three years. MSD IDEA Studios (Singapore and Berlin)